Home Medicine De novo mutation of PHEX in a type 1 diabetes patient
Article
Licensed
Unlicensed Requires Authentication

De novo mutation of PHEX in a type 1 diabetes patient

  • Chen Fang , Hui Li , Xiaozhen Li , Wenjin Xiao , Yun Huang , Wu Cai , Yi Yang and Ji Hu EMAIL logo
Published/Copyright: February 19, 2016

Abstract

A new missense mutation on the X chromosome (PHEX) at exon 4(c.442C>T) in a 4-generation Chinese Han pedigree is reported. The proband and four family members were clinically identified as the X-linked hypophosphatemic rickets (XLH) which is a dominant inherited disorder characterized by renal phosphate wasting, aberrant vitamin D metabolism, and abnormal bone mineralization. The proband is identified as hemizygous with the four female family members to be heterozygous genotypes. The discovery was made through the complete sequencing of the exons and the intron-exon boundaries of the PHEX gene of this family. The mutation caused the S141 residue to change to Phe from Ser which is perfectly conserved among humans, mice, rats, cows and chickens. PolyPhen-2 software analysis of the mutation indicated it was probably damaging. The proband was also diagnosed with type 1 diabetes (T1D) and the relationship between XLH and diabetes phenotypes was discussed in the paper.


Corresponding author: Ji Hu, Department of Endocrinology, 2nd Affiliated Hospital of Soochow University, Suzhou, 215004, P.R. China, E-mail:
aChen Fang, Hui Li and Xiaozhen Li: These authors contributed equally to this work.

References

1. Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, et al. Mutational analysis and genotype-phenotype correlation of the PHEX gene in Xlinked hypophosphatemic rickets. J Clin Endocrinol Metab 2001;86:3889–99.10.1210/jcem.86.8.7761Search in Google Scholar

2. Francis F, Henning S, Korn B, Reinhardt R, de Jong P, et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130–6.10.1038/ng1095-130Search in Google Scholar

3. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;17:1656–63.10.1056/NEJMoa020881Search in Google Scholar

4. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemicrickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957–60.10.1210/jc.2002-021105Search in Google Scholar

5. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345–8.10.1038/81664Search in Google Scholar

6. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006;38:1310–5.10.1038/ng1905Search in Google Scholar

7. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 2010;86:273–8.10.1016/j.ajhg.2010.01.010Search in Google Scholar

8. Fukumoto S, Martin TJ. Bone as an endocrine organ. Trends Endocrinol Metab 2009;20:230–6.10.1016/j.tem.2009.02.001Search in Google Scholar

9. Vervloet MG, Massy ZA, Brandenburg VM, Mazzaferro S, Cozzolino M, et al. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol 2014;2:427–36.10.1016/S2213-8587(14)70059-2Search in Google Scholar

10. Chen X, Tian HM, Pei FX, Yu XJ. Bone functions as a novel endocrine organ in energy metabolism. Chin Med J 2012;125:4117–21.Search in Google Scholar

11. Garcia-Martin A, Reyes-Garcia R, Avila-Rubio V, Munoz-Torres M. Osteocalcin: a link between bone homeostasis and energy metabolism. Endocrinol Nutr 2013;60:260–3.10.1016/j.endoen.2012.06.012Search in Google Scholar

12. Pi M, Quarles LD. Novel bone endocrine networks integrating mineral and energy metabolism. Curr Osteop Rep 2013;11:391–9.10.1007/s11914-013-0178-8Search in Google Scholar

13. Todd JA. Etiology of type 1 diabetes. Immunity 2010;32:457–67.10.1016/j.immuni.2010.04.001Search in Google Scholar

14. Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wagenstaller J, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bonematrix protein in the regulation of phosphate homeostasis. Nat Genet 2006;38:1248–50.10.1038/ng1868Search in Google Scholar

15. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocr Metab 2005;90:2424–7.10.1210/jc.2004-2238Search in Google Scholar

16. Goji K, Ozaki K, Sadewa AH, Nishio H, Matsuo M. Clinical case seminar: somatic and germline mosaicism for a mutation of the PHEX gene can lead to genetic transmission of X-linked hypophosphatemic rickets that mimics an autosomal dominant trait. J Clin Endocr Metab 2006;91:365–70.10.1210/jc.2005-1776Search in Google Scholar

17. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248–9.10.1038/nmeth0410-248Search in Google Scholar

18. Sabbagh Y, Jones AO, Tenenhouse HS. PHEXdb, a locus-specific database for mutations causing X-linked hypophosphatemia. Hum Mutat 2000;16:1–6.10.1002/1098-1004(200007)16:1<1::AID-HUMU1>3.0.CO;2-JSearch in Google Scholar

19. Tyynismaa H, Kaitila I, Nanto-Salonen K, Ala-Houhala M, Alitalo T. Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets. Hum Mutat 2000;15:383–4.10.1002/(SICI)1098-1004(200004)15:4<383::AID-HUMU18>3.0.CO;2-#Search in Google Scholar

20. Zou J, Xiong X, Lai B, Sun M, Tu X, et al. Glucose metabolic abnormality is associated with defective mineral homeostasis in skeletal disorder mouse model. Sci China Life Sci 2015;58:359–67.10.1007/s11427-015-4827-2Search in Google Scholar

21. Muhlbauer RC, Fleisch H. Abnormal renal glucose handling in X-linked hypophosphataemic mice. Clin Sci (Lond) 1991;80:71–6.10.1042/cs0800071Search in Google Scholar

22. Capparelli AW, Roh D, Dhiman JK, Jo OD, Yanagawa N. Altered proximal tubule glucose metabolism in X-linked hypophosphatemic mice. Endocrinology 1992;130:328–34.10.1210/endo.130.1.1309337Search in Google Scholar

23. Rifas L, Gupta A, Hruska KA, Avioli LV. Altered osteoblast gluconeogenesis in X-linked hypophosphatemic mice is associated with a depressed intracellular pH. Calcif Tissue Int 1995;57:60–3.10.1007/BF00298998Search in Google Scholar

24. Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, et al. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine 1989;68:336–52.10.1097/00005792-198911000-00002Search in Google Scholar

25. Rosenthall L. EXA bone densitometry measurements in adults with X-linked hypophosphatemia. Clin Nucl Med 1993;D18:564–6.10.1097/00003072-199307000-00004Search in Google Scholar

26. Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, et al. Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int 2010;87:108–19.10.1007/s00223-010-9373-0Search in Google Scholar

27. Marie PJ, Glorieux FH. Bone histomorphometry in asymptomatic adults with hereditary hypophosphatemic vitamin D-resistant osteomalacia. Metab Bone Dis Relat Res 1982;4:249–53.10.1016/0221-8747(82)90035-2Search in Google Scholar

Received: 2015-10-7
Accepted: 2015-12-14
Published Online: 2016-2-19
Published in Print: 2016-5-1

©2016 by De Gruyter

Articles in the same Issue

  1. Frontmatter
  2. Review
  3. Resistance to thyroid hormone α, revelation of basic study to clinical consequences
  4. Original Articles
  5. Improved molecular diagnosis of patients with neonatal diabetes using a combined next-generation sequencing and MS-MLPA approach
  6. Safety and metabolic impact of Ramadan fasting in children and adolescents with type 1 diabetes
  7. Waist-to-height ratio as a marker of low-grade inflammation in obese children and adolescents
  8. Classification and clinical characterization of metabolically “healthy” obese children and adolescents
  9. Long-term BH4 (sapropterin) treatment of children with hyperphenylalaninemia – effect on median Phe/Tyr ratios
  10. Compound heterozygous mutations (p.T561M and c.2422delT) in the TPO gene associated with congenital hypothyroidism
  11. Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency
  12. Urate crystals deposition in the feet of overweight juveniles and those with symptomatic hyperuricemia: a dual-energy CT study
  13. A novel ALMS1 homozygous mutation in two Turkish brothers with Alström syndrome
  14. Novel AVPR2 mutation causing partial nephrogenic diabetes insipidus in a Japanese family
  15. Pituitary gigantism: a retrospective case series
  16. Case Reports
  17. A novel OTX2 gene frameshift mutation in a child with microphthalmia, ectopic pituitary and growth hormone deficiency
  18. A novel nonsense mutation in the WFS1 gene causes the Wolfram syndrome
  19. A 33-year-old male patient with paternal derived duplication of 14q11.2–14q22.1~22.3: clinical course, phenotypic and genotypic findings
  20. Familial Turner syndrome: the importance of information
  21. De novo mutation of PHEX in a type 1 diabetes patient
  22. Congenital hypothyroidism and thyroid dyshormonogenesis: a case report of siblings with a newly identified mutation in thyroperoxidase
Downloaded on 18.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2015-0399/html
Scroll to top button